Segra Enters Agreement to Deploy Plant Tissue Culture for Large Scale Outdoor Cannabis Cultivation in Collaboration with Leading Canadian Licensed Producer

Segra Enters Agreement to Deploy Plant Tissue Culture for Large Scale Outdoor Cannabis Cultivation in Collaboration with Leading Canadian Licensed Producer

VANCOUVER, British Columbia, April 22, 2020 (GLOBE NEWSWIRE) — Segra International Corp, a cannabis agriculture technology company and a leader in cannabis plant tissue culture, is pleased to announce that it has entered into an agreement to supply a leading Canadian Licensed Producer with a curated selection of cultivars for the 2020 outdoor growing season.
Under the agreement, Segra will provide approximately 40,000 plantlets to the Licensed Producer for late spring planting. To Segra’s knowledge, this planting represents the first large scale outdoor deployment of cannabis plantlets derived directly from a plant tissue culture, anywhere in the world. Additionally, this agreement represents further validation of Segra’s go-to-market strategy where primary compensation is derived through production-based royalties, and a balanced risk-reward partnership is fostered between the parties.Plant tissue culture, also known as micropropagation, is a modern agricultural technology developed primarily to help scale up clonally produced crops where young plants are cultured in aseptic laboratory conditions rather than from mother stock plants. The precision laboratory conditions allow for both enhanced control of plant diseases and the ability to manufacture millions of true-to-type plantlets in a compact, predictable, and scalable workflow. Most clonally produced crops in the world, from strawberries to orchids, have benefited immensely from plant tissue culture. Cannabis is the next crop to take advantage of this proven technology. The application of Segra’s proprietary tissue culture technology creates a level of quality and consistency that sets a new bar for the industry. Additionally, Segra’s quality assurance program ensures that every outgoing batch of plantlets is screened for common cannabis plant diseases, and DNA fingerprinting is conducted to verify cultivar accuracy.“Our core objective at Segra is to become long-term trusted partners with our clients and engage in a reasonable exchange of value,” said Segra’s Director of Global Business Development, Ian Davidson. “Segra’s production-based royalty model makes this vision a reality by directly aligning the risk/reward profile of both companies, while also giving our team at Segra a strong incentive to help our customers achieve success at every stage through leveraging our knowledge base and cannabis network.”Plant tissue culture will become the proven way to meet sustainable production metrics in large scale cannabis cultivation as it reduces the infrastructure and expense required while mitigating the pathogen risks of traditional vegetative propagation. Compounded by the current COVID-19 pandemic, cultivators are seeing the harsh realities of scaling these legacy propagation methods and are looking for solutions. The cannabis industry is ripe to embrace the big-ag-tech playbook and evolve towards nursery-to-grower model where specialization, collaboration, and trust create improved value and mutual long-term success.“We are excited at the opportunity to collaborate with Canadian and International LP’s to demonstrate the importance of plant tissue culture to the cannabis industry,” said Jamie Blundell, CEO of Segra “Along with this large scale contract, we will be working together to test several new cultivars in Segra’s R&D pipeline that will identify additional proven winners for outdoor production offerings in 2021. As we continue to execute agreements like this, our disruptive plantlet technology will soon become the best practice for indoor, greenhouse and outdoor cannabis cultivation.”About Segra InternationalSegra is an agriculture technology company offering plant tissue culture and DNA fingerprinting services to accelerate the advancement of the cannabis industry. The Company’s proprietary technologies empower its clients to drive financial performance and mitigate risk, while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce disease-free, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally. To support this vision, Segra has assembled a world-class team of specialists in the fields of agronomy, molecular genetics, plant tissue culture, and regulatory compliance. Learn more at www.segra-intl.comContact For Further InformationCarson Otto
Email: carson.otto@segra-intl.com
Forward-Looking InformationThis news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
CBJ Newsmakers

Recommended
Teck Reports Voting Results from Annual General MeetingIFIC Monthly Investment Fund Statistics – March 2020